GEORGE WASHINGTON UNIVERSITY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1821-01-01
- Employees
- 6.2K
- Market Cap
- -
- Website
- http://www.gwu.edu
Clinical Trials
177
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (138 trials with phase data)• Click on a phase to view related trials
ChatGPT-Supported Text Messaging Program for Smoking Cessation
- Conditions
- Smoking Cessation
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 150
- Registration Number
- NCT07079306
HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs) in Nigeria
- Conditions
- HIV
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 400
- Registration Number
- NCT07000513
- Locations
- 🇳🇬
National Institute of Medical Research, Lagos, Nigeria
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
- Conditions
- Weight LossGestational Diabetes Mellitus in PregnancyPostpartum Care
- Interventions
- Behavioral: Enhanced Lifestyle InterventionBehavioral: Lifestyle Intervention
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 60
- Registration Number
- NCT06948825
- Locations
- 🇺🇸
Milken Institute School of Public Health - The George Washington University, Washington, District of Columbia, United States
Changing Youth Narratives on Firearm Violence ("Run It Up") Intervention
- Conditions
- Injury Prevention
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 1000
- Registration Number
- NCT06940362
- Locations
- 🇺🇸
George Washington University Milken Institute School of Public Health, Washington, District of Columbia, United States
Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
- Conditions
- Lung Cancers
- Interventions
- Drug: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)Drug: Intercostal nerve block
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 120
- Registration Number
- NCT06810375
- Locations
- 🇺🇸
The George Washington University Hospital, Washington, District of Columbia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 35
- Next
News
FDA Expert Panel Calls for Revision of Menopausal Hormone Therapy Warning Labels
An FDA expert panel convened to reassess boxed warnings for menopausal hormone therapy, with multiple experts arguing that current labels overstate risks and are not supported by comprehensive scientific evidence.
Nanochon Receives Health Canada Approval for First-in-Human Trial of 3D Printed Knee Cartilage Implant
Nanochon has received Health Canada approval for a first-in-human clinical trial of its 3D printed Chondrograft implant to treat articular cartilage defects in the knee.
Breathe BioMedical Initiates Major Clinical Trial for Innovative Breast Cancer Breath Test
Breathe BioMedical launches multi-center clinical trial at George Washington University Breast Center to develop a breath-based detection test for breast cancer in women with dense breast tissue.
Trastuzumab Deruxtecan Shows Promise in HER2-Expressing Metastatic Prostate Cancer: A Case Study
• A case study reports a 57% reduction in tumor volume in a metastatic prostate cancer patient treated with trastuzumab deruxtecan (T-DXd). • The patient, who had stage four metastatic prostate cancer and failed multiple lines of therapy, showed significant improvement after T-DXd treatment. • The study highlights the potential of T-DXd in aggressive prostate cancer and the importance of HER2 expression testing. • This is the first known case of using T-DXd for prostate cancer treatment, offering a potential new therapeutic avenue.
Novel HIV Vaccine Shows 97% Antibody Response Rate in Phase 1 Trial
A groundbreaking HIV vaccine using "germline targeting" successfully generated antibodies in 97% of participants in a Phase 1 trial, with no severe side effects reported.